Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy
Baseline <sup>18</sup>F-flotufolastat-PET metrics and pretherapeutic clinical parameters are key prognostic factors for severe hematologic toxicity in mCRPC patients treated with [<sup>177</sup>Lu]Lu-PSMA-I&T.
Authors
- Robert Tauber (ORCID: https://orcid.org/0000-0002-4770-3307)
- Matthias Heck (ORCID: https://orcid.org/0000-0002-5754-0628)
- Isabel Rauscher (ORCID: https://orcid.org/0000-0003-4655-2153)
- Matthias Eiber (ORCID: https://orcid.org/0000-0003-2130-644X)
- Calogero D ́Alessandria
- Bernhard Haller (ORCID: https://orcid.org/0000-0002-9723-393X)
- Amir Karimzadeh (ORCID: https://orcid.org/0000-0002-7055-8275)
- Stefan Hein
- Kimberley J. Hansen
Institutions
- Technical University of Munich (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-05-18
- DOI
- https://doi.org/10.1007/s00259-025-07200-7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00